TY  - ADVS
AU  - Druker,Brian J.
TI  - Imatinib as a paradigm of targeted cancer therapies
T2  - Signal transduction via protein tyrosine kinase receptors : structures, function, regulation, mechanisms and role in disease,
PY  - 2007///
CY  - London
PB  - Henry Stewart Talks
KW  - Antineoplastic agents
KW  - Cellular signal transduction
KW  - Chronic myeloid leukemia
KW  - Chemotherapy
KW  - Protein kinases
KW  - Inhibitors
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - imatinib
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - drug therapy
KW  - Molecular Targeted Therapy
KW  - Receptor Protein-Tyrosine Kinases
KW  - Signal Transduction
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Contents: Clinical description of chronic myeloid leukemia (CML) -- Molecular pathogenesis of CML -- The BCR-ABL tyrosine kinase as a therapeutic target -- Preclinical and clinical development of the ABL tyrosine kinase inhibitor, imatinib -- Mechanisms of resistance to imatinib -- Development of novel ABL tyrosine kinase inhibitors for imatinib-resistant CML -- Imatinib and gastrointestinal stromal tumor -- Extending the imatinib paradigm -- Lessons learned from the clinical trials of imatinib; Access restricted to subscribers
UR  - https://hstalks.com/bs/464/
UR  - https://hstalks.com/bs/p/38/
UR  - https://hstalks.com/bs/p/739/
ER  -